After 24 weeks of rosuvastatin , we found significant decreases in plasma levels of soluble CD14 ( -13.4 % vs 1.2 % , P = .002 ) and in proportions of tissue factor-positive patrolling ( CD14 ( Dim ) CD16 ( + ) ) monocytes ( -38.8 % vs -11.9 % , P = .04 ) in rosuvastatin-treated vs placebo-treated subjects .